Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Open-label Trial Comparing OnDose® AUC Optimized 5-FU Based Administration Versus Standard Body Surface Area (BSA) Dosing in Metastatic Colorectal Cancer Patients (mCRC) Treated With mFOLFOX6

NCT01468623 is registered in ClinicalTrials.gov with Myriad Genetic Laboratories, Inc. as lead sponsor.

NCT NCT01468623
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01468623 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Open-label Trial Comparing OnDose® AUC Optimized 5-FU Based Administration Versus Standard Body Surface Area (BSA) Dosing in Metastatic Colorectal Cancer Patients (mCRC) Treated With mFOLFOX6
Lead sponsor
Myriad Genetic Laboratories, Inc.
Phase
Phase 4
Overall status
Terminated
Start date
September 30, 2011
Completion date
August 31, 2012
Enrollment
51 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, metastatic